US008067416B2

(12) **United States Patent**
Oppenheimer et al.

(10) **Patent No.: US 8,067,416 B2**
(45) **Date of Patent: *Nov. 29, 2011**

(54) **METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS**

(75) Inventors: **Daniel I. Oppenheimer**, Castro Valley, CA (US); **Emil D. Kakkis**, Novato, CA (US); **Fredric D. Price**, Bedford, NY (US); **Alejandro Dorenbaum**, Mill Valley, CA (US); **Rudolf Moser**, Schaffhausen (CH); **Viola Groehn**, Dachsen (CH); **Thomas Egger**, Kempthal (CH); **Fritz Blatter**, Reinach (CH)

(73) Assignees: **Merck Eprova AG**, Schaffhausen (CH); **Biomarin Pharmaceutical Inc.**, Novato, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 252 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/508,209**

(22) Filed: **Jul. 23, 2009**

(65) **Prior Publication Data**

US 2010/0009996 A1 Jan. 14, 2010

Related U.S. Application Data

(63) Continuation of application No. 11/143,887, filed on Jun. 1, 2005, now Pat. No. 7,566,714, which is a continuation of application No. 10/991,573, filed on Nov. 17, 2004, now abandoned.

(60) Provisional application No. 60/520,767, filed on Nov. 17, 2003.

(51) **Int. Cl.**

A61K 31/495	(2006.01)
A61K 31/40	(2006.01)
A61K 31/445	(2006.01)
A01N 43/54	(2006.01)

(52) **U.S. Cl.** **514/249**; 514/338; 514/419; 514/258

(58) **Field of Classification Search** 514/249
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,541,717	A		2/1951	Petering et al.
2,568,685	A		9/1951	Petering et al.
2,603,643	A		7/1952	Kirchsteiner et al.
2,955,110	A		10/1960	Patterson et al.
3,505,329	A		4/1970	Weinstock et al.
4,252,822	A		2/1981	Berry et al.
4,371,514	A		2/1983	Nagatsu et al.
4,540,783	A		9/1985	Viscontini
4,550,109	A		10/1985	Folkers et al.
4,595,752	A		6/1986	Azuma et al.
4,649,197	A		3/1987	Uchino et al.
4,713,454	A		12/1987	Sakai et al.
4,758,571	A		7/1988	Curtius et al.
4,774,244	A		9/1988	Curtius et al.
4,778,794	A		10/1988	Naruse et al.
4,920,122	A		4/1990	Naruse et al.
4,937,342	A		6/1990	Kurono et al.
4,943,575	A		7/1990	Cremer
5,037,981	A		8/1991	Kurono et al.
5,043,446	A		8/1991	Kikuchi et al.
5,198,469	A		3/1993	Sakata
5,418,192	A		5/1995	Borden et al.
5,439,799	A		8/1995	Rautenberg et al.
5,449,688	A		9/1995	Wahl et al.
5,468,630	A		11/1995	Billiar et al.
5,468,772	A		11/1995	Xu et al.
5,502,050	A		3/1996	Gross
5,554,647	A		9/1996	Perricone
5,606,020	A		2/1997	Watanabe et al.
5,643,586	A		7/1997	Perricone
5,658,565	A		8/1997	Billiar et al.
5,736,343	A	*	4/1998	Landry 435/7.6
5,744,340	A		4/1998	Fossetta et al.
5,753,656	A		5/1998	Sakai et al.
5,763,392	A		6/1998	Hansen et al.
5,830,461	A		11/1998	Billiar et al.
5,846,775	A		12/1998	Hillman et al.
5,856,158	A		1/1999	Rosazza et al.
5,875,433	A		2/1999	Gross
5,877,176	A		3/1999	Gross
5,879,690	A		3/1999	Perricone
5,880,124	A		3/1999	Gross
5,882,908	A		3/1999	Billiar et al.
5,902,810	A		5/1999	Pfleiderer et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 108 890	5/1984

(Continued)

OTHER PUBLICATIONS

Bates et al., Medical Administration: The Correct Way, in Children's Medications, A Parent's Guide, Harvey Whitney Books Company, Cincinnati, Ohio (1996) pp. 1-27. Belanger-Quintana et al., "Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: Evolution of seven patients on long-term treatment with tetrahydrobiopterin," Molecular Genetics and Metabolism, 86:S61-S66 (2005).

Bellamy et al., "Oral folate enhances endothelial function in hyperhomocysteinarmic subjects," Eur J Clin Invest., 29(8), pp. 659-662 (1999).

Bernegger et al., "High Frequency of Tetradrobiopterin-responsiveness Among Hyperphenylalaninemias: a Study of 1919 Patients Observed from 1988 to 2002," Molecular Genetics and Metabolism, 77, pp. 304-313 (2002).

(Continued)

Primary Examiner — Sreeni Padmanabhan
Assistant Examiner — Timothy E Betton
(74) *Attorney, Agent, or Firm* — Marshall, Gerstein & Borun LLP

(57) **ABSTRACT**

The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

24 Claims, 20 Drawing Sheets